Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
1 CE
Learning Objectives:
Describe the clinical rationale for using naturopathic interventions during watchful waiting in early-stage chronic lymphocytic leukemia (CLL), monoclonal gammopathy of undetermined significance (MGUS), and smouldering multiple myeloma (SMM).
Summarize current evidence on specific natural agents—including green tea polyphenols, vitamin D, curcumin, and omega-3 fatty acids—that have been studied in the context of delaying disease progression in these conditions.
Evaluate the emerging role of dietary strategies and microbiome modulation (e.g., high-fibre, plant-based diets) in early-stage hematologic malignancies and their potential to support metabolic and inflammatory biomarkers.
Identify appropriate patient populations and clinical scenarios in which naturopathic strategies may safely complement conventional surveillance protocols.
Discuss the limitations of current research and highlight opportunities for future investigation into integrative, evidence-informed approaches for managing indolent blood cancers.
1 CE
Learning Objectives:
Describe the clinical rationale for using naturopathic interventions during watchful waiting in early-stage chronic lymphocytic leukemia (CLL), monoclonal gammopathy of undetermined significance (MGUS), and smouldering multiple myeloma (SMM).
Summarize current evidence on specific natural agents—including green tea polyphenols, vitamin D, curcumin, and omega-3 fatty acids—that have been studied in the context of delaying disease progression in these conditions.
Evaluate the emerging role of dietary strategies and microbiome modulation (e.g., high-fibre, plant-based diets) in early-stage hematologic malignancies and their potential to support metabolic and inflammatory biomarkers.
Identify appropriate patient populations and clinical scenarios in which naturopathic strategies may safely complement conventional surveillance protocols.
Discuss the limitations of current research and highlight opportunities for future investigation into integrative, evidence-informed approaches for managing indolent blood cancers.